Vertex Pharmaceuticals, Inc.

Ted Fox

Joseph L Kim

Chao Lin

Keith P Wilson

Ursula A Germann

John Allan Thomson

Kurt A Morgenstern

Michael Shin-San Su

The invention relates to methods for designing inhibitors of serine/threonine kinases and tyrosine kinases, particularly MAP kinases, through the use of ATP-binding site mutants of those kinases. The methods of this invention take advantage of the fact that the mutant kinases are capable of binding inhibitory compounds of other kinases with greater affinity than the corresponding wild-type kinase. The invention further relates to the mutant kinases themselves and crystallizable co-complexes of the mutant kinase and the inhibitory compound.

Methods for designing inhibitors of serine/threonine kinases and tyrosine kinases

The present invention relates to compositions and crystals of a hepatitis C virus protease in complex with its viral cofactor. This invention also relates to methods of using the structure coordinates of hepatitis C virus protease in complex with a synthetic NS4A to solve the structure of similar or homologous proteins or protein complexes.

Crystallizable compositions comprising a hepatitis C virus NS3 protease domain/NS4A complex

Methods for designing inhibitors of serine/threonine-kinases and

Crystallizable compositions comprising a hepatitis C virus NS3 protease

Growing community of inventors

Maynard, MA, United States of America

Ted Fox